Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence
- PMID: 18583175
- DOI: 10.1016/j.parkreldis.2008.04.023
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence
Abstract
Clinical evidence suggests that stimulation of the D(1) rather than D(2) dopamine receptor is related to the development of dyskinesias in Parkinson's disease (PD). We evaluated, in the 6-hydroxydopamine rat model of PD, sensitization of contralateral turning (SCT) behaviour and abnormal involuntary movements (AIMs) as behavioural parameters of dyskinetic response, and changes in zif-268 mRNA expression in striatonigral and striatopallidal neurons on subchronic administration of the D(2)/D(3) agonist ropinirole, defined as a mild dyskinetic drug in the clinic. Results were compared with previous findings on repeated L-dopa treatment. Ropinirole displayed a mild dyskinetic response characterized by SCT only, which contrasted with the presence of SCT in association with AIMs elicited by repeated L-dopa. Zif-268 mRNA levels were decreased in both striatonigral and striatopallidal neurons by ropinirole, in contrast to hyper-expression of zif-268 mRNA selectively induced by L-dopa in striatonigral neurons. Unbalanced responsiveness of striatal efferent neurons might represent a molecular correlate of high dyskinetic potential and AIMs in rats; in contrast, a balanced striatal output might underlie the low dyskinetic potential displayed by ropinirole.
Similar articles
-
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.Synapse. 2008 Jul;62(7):524-33. doi: 10.1002/syn.20527. Synapse. 2008. PMID: 18435422
-
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.Eur J Neurosci. 2005 Mar;21(5):1196-204. doi: 10.1111/j.1460-9568.2005.03944.x. Eur J Neurosci. 2005. PMID: 15813929
-
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.Exp Neurol. 2010 Aug;224(2):395-402. doi: 10.1016/j.expneurol.2010.04.016. Epub 2010 May 7. Exp Neurol. 2010. PMID: 20452347
-
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.Parkinsonism Relat Disord. 2008;14 Suppl 2:S159-64. doi: 10.1016/j.parkreldis.2008.04.022. Parkinsonism Relat Disord. 2008. PMID: 18638717 Review.
-
Molecular mechanisms of L-DOPA-induced dyskinesia.Nat Rev Neurosci. 2008 Sep;9(9):665-77. doi: 10.1038/nrn2471. Nat Rev Neurosci. 2008. PMID: 18714325 Review.
Cited by
-
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.Mov Disord. 2019 Dec;34(12):1818-1830. doi: 10.1002/mds.27799. Epub 2019 Jul 23. Mov Disord. 2019. PMID: 31335998 Free PMC article.
-
Differential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development.J Neurosci. 2024 Jun 26;44(26):e0050242024. doi: 10.1523/JNEUROSCI.0050-24.2024. J Neurosci. 2024. PMID: 38664012 Free PMC article.
-
Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.Biochem Pharmacol. 2011 Oct 15;82(8):873-82. doi: 10.1016/j.bcp.2011.06.001. Epub 2011 Jun 13. Biochem Pharmacol. 2011. PMID: 21684266 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources